Leading the Future of Precision Immunotherapy
Alithea Bio: Pioneering HLA peptide Characterization with Innovative Immunopeptidomics, highly sensitive Mass Spectrometry and applied AI
HLA-Compass
Navigate the Immunopeptidome with Confidence
HLA-Compass is the world’s largest immunopeptidomics database, designed to guide drug developers through the complexity of immune-target interactions. By combining high-throughput mass spectrometry with curated healthy and tumor tissue data, HLA-Compass helps you identify true targets, assess off-target toxicity, and de-risk your immunotherapy pipeline — all in one powerful platform.
Our Commitment
We are world leaders in HLA peptide quantification, enhancing the precision and effectiveness of therapeutic solutions to ensure safer and more effective options for patients. Alithea Bio is at the forefront of revolutionizing cancer treatment through groundbreaking T-cell therapies.
Our Goal
We aim for a future where innovative TCR therapies and a comprehensive HLA peptide database enable more effective and safer cancer treatments.
Alithea Bio combines cutting-edge immunopeptidomics methods, highly sensitive mass spectrometry, and AI to provide world-leading results in the characterization of HLA peptides from cell lines, tissues, and blood.
Solutions
Clinical Safety
Off-target toxicity prediction Off-target quantification TCRm HLA peptide purificationImmunogenicity
Protein therapeuticsProducts
Our product suite empowers immunotherapy developers with end-to-end solutions — from raw patient tissue to clinical insight. Whether you’re searching for novel antigens, validating TCR specificity, or ensuring safety through off-target prediction, Alithea Bio delivers the tools to move faster, with greater precision.
Explore our SaaS platform, mass spectrometry services, and AI-powered analytics.
HLA- Compass
Our web-accessible HLA peptide database HLA Compass comprises 1.4 million unique peptides and 10,000 cancer specific epitopes deriving from >17 million identifications in 4,160 high-quality HLA peptidomics samples, meticulously collected from healthy organs, cancer cell lines, and tumor tissues.
Learn moreHLA Peptide Binding Predictions
Predict which peptides will bind to specific HLA molecules — fast and reliably. Our AI-powered tools combine biological relevance and computational precision to support epitope discovery, vaccine design, and immunotherapy development.
Learn moreNeoZOOM
A cutting-edge mass spectrometry service for ultra-sensitive profiling of HLA peptides directly from tumor or tissue samples. NeoZOOM helps you zoom in on the targets that matter most — with unmatched depth and accuracy.
Learn moreOff-Target Toxicity Prediction
Reduce risk before it reaches the clinic. Our platform integrates proprietary healthy tissue data and machine learning models to predict potential off-target peptide binding — helping you design safer TCR, TCRm, and antibody therapies.
Learn moreKits
Standardized kits for sample preparation and peptide enrichment, tailored for HLA immunopeptidomics workflows. Designed to ensure reproducibility, scalability, and compatibility with mass spectrometry and downstream analytics.
Learn moreTechnology
Our proprietary technology combines high-sensitivity mass spectrometry with advanced bioinformatics and machine learning to reveal the full complexity of HLA-presented peptides — enabling safer, more effective drug development. From tumor profiling to target validation and toxicity prediction, we turn deep biology into actionable insight.
Explore our core technology pillars.
